Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Corbus Pharmaceuticals Holdings, Inc. CRBP

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-78.5M
$-64.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2022 · Revenue 0.0 · Net income -42.3
15M30M-50M-100M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2021 · Operating -6350.1% · Net ·
-2000%-4000%-6000%
201320192025
ROE
FY2025 · ROE -54.2%
-200%-400%
201320192025
Three returns, three denominators.

Each USD of equity lost 54 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -64.5
-50M-100M
201320192025

Total assetsUSD 168.2M
EquityUSD 147.5M
CashUSD 28.5M
Current ratio8.07×

Equity funds 88% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CRBP, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B◌◌◌0.00.00.00.00.00.00.00.0◌◌
Operating income $B−0.1−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.0−0.0−0.0−0.1−0.1−0.1◌◌−0.0−0.0−0.0◌
Income tax $B0.00.0◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.1−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $−5.90−3.68−10.31−10.15−11.15−1.42−1.12−0.98−0.65−0.49−0.28−0.13−0.09
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−54.2——−83.0−79.8−432.7−424.3−130.5−97.2−223.4−119.2——
Shares out B0.020.010.000.000.130.100.060.060.060.040.040.030.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 52 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image